Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -48.60% is 20% below its 5-year average of -40.66%, around the middle of its 5-year range (-66.31%–-14.05%).
18.52% above its 12-month average of -59.64%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.78%.
RETURN ON ASSETS (ROA)
-48.60%
RETURN ON ASSETS (ROA) AVG TTM
-59.64%
RETURN ON ASSETS (ROA) AVG 3Y
-46.49%
RETURN ON ASSETS (ROA) AVG 5Y
-40.66%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+18.52%
CURRENT VS 3Y AVG
-4.54%
CURRENT VS 5Y AVG
-19.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.81%
median of 841 covered companies
CURRENT VS SECTOR MEDIAN
-52.78%
vs the sector median at left
Pliant Therapeutics, Inc.
Market Cap
$63.16M
Return on Assets (ROA)
-48.60%
TTM Avg
-59.64%
3Y Avg
-46.49%
5Y Avg
-40.66%
Market Cap
$63.23M
Return on Assets (ROA)
-39.17%
TTM Avg
-30.96%
3Y Avg
-31.81%
5Y Avg
-21.33%
Market Cap
$63.35M
Return on Assets (ROA)
-13.50%
TTM Avg
-6.86%
3Y Avg
-33.98%
5Y Avg
-45.40%
Market Cap
$63.79M
Return on Assets (ROA)
-5.05%
TTM Avg
-7.03%
3Y Avg
-4.31%
5Y Avg
-4.67%
Market Cap
$64.20M
Return on Assets (ROA)
-107.09%
TTM Avg
-123.27%
3Y Avg
-270.15%
5Y Avg
-219.64%
Market Cap
$64.49M
Return on Assets (ROA)
-162.91%
TTM Avg
-58.42%
3Y Avg
-64.67%
5Y Avg
-61.98%
Market Cap
$61.06M
Return on Assets (ROA)
-44.47%
TTM Avg
-42.63%
3Y Avg
-230.85%
5Y Avg
-167.04%
Market Cap
$62.69M
Return on Assets (ROA)
-128.88%
TTM Avg
-89.84%
3Y Avg
-89.26%
5Y Avg
-80.42%
Market Cap
$60.49M
Return on Assets (ROA)
-14.15%
TTM Avg
-52.30%
3Y Avg
-73.34%
5Y Avg
-79.94%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pliant Therapeutics, Inc. (PLRX) | $63.16M | -48.60% | -59.64% | -46.49% | -40.66% |
| Alps Group Inc (ALPS)vs › | $63.23M | -39.17% | -30.96% | -31.81% | -21.33% |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.35M | -13.50% | -6.86% | -33.98% | -45.40% |
| InterCure Ltd. (INCR)vs › | $63.79M | -5.05% | -7.03% | -4.31% | -4.67% |
| RenovoRx, Inc. (RNXT)vs › | $64.20M | -107.09% | -123.27% | -270.15% | -219.64% |
| Gossamer Bio, Inc. (GOSS)vs › | $64.49M | -162.91% | -58.42% | -64.67% | -61.98% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.06M | -44.47% | -42.63% | -230.85% | -167.04% |
| Fractyl Health, Inc. (GUTS)vs › | $62.69M | -128.88% | -89.84% | -89.26% | -80.42% |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | -14.15% | -52.30% | -73.34% | -79.94% |
| Cingulate Inc. (CING)vs › | $66.27M | -87.09% | -130.17% | -272.35% | -217.34% |
ROA
-48.6%
ROE
-62.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -66.31% |
| 2024-12-31 | -52.98% |
| 2023-12-31 | -31.50% |
| 2022-12-31 | -35.17% |
| 2021-12-31 | -43.97% |
| 2020-12-31 | -14.05% |
| 2019-12-31 | -0.53% |
| 2018-12-31 | -45.51% |
| 2017-12-31 | -314.70% |
